scholarly journals Welfare Assessment, End-Point Refinement and the Effects of Non-Aversive Handling in C57BL/6 Mice with Lewis Lung Cancer

Animals ◽  
2021 ◽  
Vol 12 (1) ◽  
pp. 23
Author(s):  
Amy L. Miller ◽  
Johnny V. Roughan
Keyword(s):  
Lung Cancer ◽  
Data Quality ◽  
Effective Means ◽  
Therapeutic Interventions ◽  
Lewis Lung Cancer ◽  
Beneficial Effects ◽  
General Welfare ◽  
Welfare Evaluation ◽  
Welfare Problem ◽  
Building Capability

Cancer-bearing mice are at risk of developing anxiety, pain, or malaise. These conditions may not only harm welfare but could also undermine data quality and translational validity in studies to develop therapeutic interventions. We aimed to establish whether, or at what point mice developing lung cancer show these symptoms, what measures can best detect their onset, and if data quality and animal welfare can be enhanced by using non-aversive handling (NAH). Welfare was monitored using various daily methods. At the beginning and end of the study, we also scored behaviour for general welfare evaluation, recorded nociceptive thresholds, and applied the mouse grimace scale (MGS). Cancer caused a decline in daily welfare parameters (body weight, and food and water consumption) beginning at around 4 days prior to euthanasia. As cancer progressed, rearing and walking declined to a greater extent in cancer-bearing versus control mice, while grooming, inactive periods, and MGS scores increased. A decline in nest building capability and food consumption provided a particularly effective means of detecting deteriorating welfare. These changes suggested a welfare problem arose as cancer developed, so similar studies would benefit from refinement, with mice being removed from the study at least 4 days earlier. However, the problem of highly varied tumour growth made it difficult to determine this time-point accurately. There were no detectable beneficial effects of NAH on either data quality or in terms of enhanced welfare.

1,25(OH) 2 D 3 attenuates sleep disturbance in mouse models of Lewis lung cancer, in silico and in vivo

2021 ◽  
Author(s):  
Min Ai ◽  
Shuang‐shuang Li ◽  
Hong Chen ◽  
Xi‐ting Wang ◽  
Jiang‐nan Sun ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Sleep Disturbance ◽  
Mouse Models ◽  
In Silico ◽  
Lewis Lung ◽  
Lewis Lung Cancer

scholarly journals Small Cell Lung Cancer in Elderly Patients: A Review

2008 ◽  
Vol 6 (3) ◽  
pp. 333-344 ◽  
Author(s):  
Taofeek K. Owonikoko ◽  
Suresh Ramalingam
Keyword(s):  
Lung Cancer ◽  
Elderly Patients ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Therapeutic Interventions ◽  
Small Cell Lung ◽  
Platinum Based Chemotherapy ◽  
Thoracic Radiation ◽  
Modality Approach

Small cell lung cancer (SCLC) accounts for approximately 13% of all lung cancer cases. Approximately 40% of those cases are diagnosed in patients older than 70 years, and this proportion continues to rise in contrast to the continued decline in incidence of SCLC among the general population. The optimal strategy to manage limited-stage SCLC involves a combined modality approach with platinum-based chemotherapy and external-beam thoracic radiation therapy. For extensive-stage disease, platinum-based combination chemotherapy is a mainstay of therapy. Elderly patients present unique challenges in terms of drug metabolism and organ reserve, which impact the outcome of therapeutic interventions. However, limited data are available to guide management decisions for SCLC in elderly patients, and therefore this article discusses recommendations for treatment.

scholarly journals Antitumor effects of nadroparin combined with radiotherapy in Lewis lung cancer models

2018 ◽  
Vol Volume 11 ◽  
pp. 5133-5142 ◽  
Author(s):  
Xibing Zhuang ◽  
Tiankui Qiao ◽  
Sujuan Yuan ◽  
Qi Zhang ◽  
Wei Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lewis Lung ◽  
Lewis Lung Cancer ◽  
Antitumor Effects ◽  
Cancer Models

scholarly journals Clinical significance of circulating tumor cells and metabolic signatures in lung cancer after surgical removal

2020 ◽  
Author(s):  
Dawei Yang ◽  
Xiaofang Yang ◽  
Yang Li ◽  
Peige Zhao ◽  
Rao Fu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Early Stage ◽  
Effective Means ◽  
Disease Recurrence ◽  
Metabolic Changes ◽  
Surgical Removal ◽  
Targeted Metabolomics ◽  
Post Surgery

Abstract Background Lung cancer (LC) remains the deadliest form of cancer globally. While surgery remains the optimal treatment strategy for individuals with early-stage LC, what the metabolic consequences are of such surgical intervention remains uncertain. Methods Negative enrichment-fluorescence in situ hybridization (NE-FISH) was used in an effort to detect circulating tumor cells (CTCs) in pre- and post-surgery peripheral blood samples from 51 LC patients. In addition, targeted metabolomics analyses, multivariate statistical analyses, and pathway analyses were used to explore surgery-associated metabolic changes. Results LC patients had significantly higher CTC counts relative to healthy controls with 66.67% of LC patients having at least 1 detected CTC. CTC counts were associated with clinical outcomes following surgery. In a targeted metabolomics analysis, we detected 34 amino acids, 164 lipids, and 24 fatty acids. When comparing LC patients before and after surgery to control patients, metabolic shifts were detected via PLS-DA and pathway analysis. Further surgery-associated metabolic changes were identified when comparing LA and LB groups. We identified SM 42:4, Ser, Sar, Gln, and LPC 18:0 for inclusion in a biomarker panel for early-stage LC detection based upon an AUC of 0.965 (95% CI = 0.900–1.000). This analysis revealed that SM 42:2, SM 35:1, PC (16:0/14:0), PC (14:0/16:1), Cer (d18:1/24:1), and SM 38:3 may offer diagnostic and prognostic benefits in LC. Conclusions These findings suggest that CTC detection and plasma metabolite profiling may be an effective means of diagnosing early-stage LC and identifying patients at risk for disease recurrence.

scholarly journals Liposomal drug delivery system as an effective treatment approach for lung cancer

2020 ◽  
Vol 10 (3-s) ◽  
pp. 367-370
Author(s):  
Kinjal Patel ◽  
Devanshi Patel
Keyword(s):  
Lung Cancer ◽  
Drug Delivery ◽  
Drug Loading ◽  
Chemotherapeutic Agents ◽  
The Body ◽  
Therapeutic Interventions ◽  
Target Delivery ◽  
Liposomal Drug ◽  
Cancer Management ◽  
Important Field

Worldwide, cancer is one of the leading causes of mortality and cancer rates are set to increase at alarming rate globally. There are various types of cancer in which the leading type is the lung cancer.   In recent years lipid-based carriers, such as liposomes, have successfully encapsulated chemotherapeutic agents ameliorating some toxicity issues, while enhancing the overall therapeutic activity in cancer patients. In addition to this, nanomaterials can help to improved half-life in the body, morphology, for increased drug loading and many other ways. The survey discussed in this review will lead the anticancer therapy and cancer management which will provide the platform to the next generation.  Therefore, this critical review includes the therapeutic interventions, liposomes target delivery, active and passive drug loading. Finally, we attempt to summarize the current challenges in nanotherapeutics and provide an outlook on the future of this important field. Keywords: Drug Delivery, Liposomes target Delivery, Nanostructures, Drug loading

Combination of DNA demethylation and chemotherapy to trigger cell pyroptosis for inhalation treatment of lung cancer

Nanoscale ◽  
2021 ◽  
Author(s):  
Beibei Xie ◽  
Tingting Liu ◽  
Shuang Chen ◽  
Yan Zhang ◽  
Dongxian He ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Immune Response ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Effective Means ◽  
Dna Demethylation ◽  
Local Immune Response ◽  
Anticancer Efficacy

Pyroptosis is an inflammation-dependent and self-cascade amplifying type of programmed cell death, serving as an effective means for activating the local immune response and improving the anticancer efficacy. As the...

Blood Flow Does Not Correlate with the Size of Metastasis in Our New Intravital Observation Model of Lewis Lung Cancer

2002 ◽  
Vol 64 (1) ◽  
pp. 32-37 ◽  
Author(s):  
Hiroya Hatakawa ◽  
Naoya Funakoshi ◽  
Masataka Onizuka ◽  
Kennichi Yanagi ◽  
Norio Ohshima ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Blood Flow ◽  
Observation Model ◽  
Lewis Lung ◽  
Lewis Lung Cancer
Sign in / Sign up

Export Citation Format

Share Document